Sernova Corp T.SVA

VCTX210

[Ekenbullets]

Anyone heard anything about an update of VCTX210 which where to end in dec?

[BioTeck]

https://www.globenewswire.com/news-release/2022/02/02/2377646/0/en/CRISPR-Therapeutics-and-ViaCyte-Inc-Announce-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Novel-Gene-Edited-Cell-Replacement-Therapy-for-Treatment-of-Type-1-Diabetes-T1D.html https://www.healthline.com/diabetesmine/viacyte-diabetes-functional-cure

[Ekenbullets]

Thanks, I know about the study what Im interested in is any output from it. Think it ended december. 

[BioTeck]

The immuno suppression  is being done at a macro level on the device. My guess is that it won't work out very well, if at all. Viacyte likely knew this too and probably sold themselves to Vertex prior to starting that trial so they could cash out. Vertex is working with CRISPR on gene edited cells but that is still in preclinical stage. Not to mention their cells are embryonic which pose

[Ekenbullets]

Vctx210 is with crispr and phase 1 clinical, should have ended in dec. Waiting for some results. 

[BioTeck]

You are mistaken unless you're talking about preclinical results. That is still a pie in the sky dream for vertex as it is for sernova.